Squamous Cell Carcinoma

The addition of stereotactic body radiation therapy to nivolumab did not improve outcomes among a cohort of patients with metastatic head and neck squamous cell carcinoma, according to a study published in Journal of Clinical Oncology.

Neoadjuvant photodynamic therapy before surgery for squamous cell carcinoma in situ may facilitate simpler surgical interventions, according to a presentation at the American Society for Dermatologic Surgery annual meeting.

Pembrolizumab monotherapy appeared to be effective and safe as first-line treatment for patients with unresectable cutaneous squamous cell carcinoma, according to results of a phase 2 study published in Journal of Clinical Oncology.

Patients who underwent an organ transplant and were diagnosed with conjunctival squamous cell carcinoma presented with greater tumor thickness and larger basal diameter compared with patients who did not undergo an organ transplant.

A label change for the diuretic hydrochlorothiazide has been approved to include a small risk for non-melanoma skin cancer, the FDA announced in a press release.

Both surgery and radiation therapy were beneficial methods of treating early-stage lip squamous cell carcinoma, according to findings presented at the American Academy of Dermatology virtual meeting.

Black patients with esophageal cancer had a lower likelihood of receiving surgical intervention for resectable disease than their white counterparts, according to results of a retrospective study published in Journal of Gastrointestinal Surgery.

Mohs micrographic surgery was superior to wide local excision as measured by local recurrence rates in a cohort of patients with T2a squamous cell carcinoma, according to a study.

Pembrolizumab in combination with radiotherapy conferred promising survival outcomes with acceptable toxicity among patients with locally advanced head and neck squamous cell carcinoma, according to results of a single-arm phase 2 study presented at Multidisciplinary Head and Neck Cancers Symposium.

Neoadjuvant nivolumab with or without ipilimumab appeared effective and safe for patients with resectable oral cavity cancer, according to results of a randomized phase 2 study presented at Multidisciplinary Head and Neck Cancers Symposium.